Summary

Next Generation Sequencing Market Trends & Summary

Next Generation Sequencing market is expected to reach US$ 56.25 billion by 2033 from US$ 12.52 billion in 2024, with a CAGR of 18.17% from 2025 to 2033. Because of continuous technological breakthroughs, growing clinical applications, increased need for data analysis and bioinformatics tools, a growing emphasis on precision medicine, and increased research and development initiatives, the market for NGS is growing quickly.

The report Next-Generation Sequencing Market & Forecast covers by Products (Instruments, Reagents & Consumables, and Services), Application (Diagnostics, Agriculture and Animal Research, Drug Discovery, Personalized Medicine and Genetic Screening), Technology (Sequencing by Synthesis, Ion Semiconductor, Single-Molecule Read Time, Nanopore), End-Users (Academic and Clinical Research Centers, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, and Others), Country and Company Analysis 2025-2033.


Next Generation Sequencing Industry Overview

Massive parallelism is used in next-generation sequencing to sequence millions or even billions of DNA strands. High throughput sequencing is another name for this technique. Compared to Sanger genome sequencing, NGS is less reliant on fragment-cloning techniques. The advantages of NGS over Sanger’s sequencing approach include low cost, great accuracy and speed, exact findings even if little amounts of material are employed. As a result, NGS finds extensive application in agriculture, animal research, customized medicine, cancer research, and biomarker development.

Understanding how COVID-19 spreads has also been accomplished by genome sequencing, which can also help determine how interventions impact the course of the disease and the effectiveness of later treatments. In March 2020, the Covid-19 Genomics U.K. Consortium (COG-U.K.) was established to study the coronavirus genome using Whole-Genome Sequencing. The NHS, Public Health Agencies, the Welcome Sanger Institute, and other academic institutions are partners in the collaboration. These groups have worked together to map the development and dissemination of the virus.

The World Health Organization (WHO) announced that there were over 275,233,892 confirmed cases of COVID-19 worldwide as of December 22, 2021. Additionally, it is projected that the growing number of cancer cases globally will support the market for next-generation sequencing. This is due to the growing importance of platforms based on NGS technology for the identification of cancer biomarkers. In 2020, there were about 19,292,789 new instances of cancer discovered worldwide, according to data released by the GLOBOCAN database.

Furthermore, during the projected period, the market for Nex Generation Sequencing is anticipated to benefit from product approvals based on NGS technology for the identification of a variety of ailments, including genetic disorders and infectious diseases. Thermo Fisher Scientific's Oncomine Dx Target test, for example, received pre-market approval from the US FDA on September 8, 2020, as a companion diagnostic (CDx) to identify patients with metastatic non-small cell lung cancer (NSCLC) who have RET fusion and are candidates for Blueprint Medicines' targeted therapy GAVRETOTM (pralsetinib). It is the first CDx for biomarkers linked to three FDA-approved NSCLC treatments based on targeted next-generation sequencing (NGS).


Growth Drivers for the Next Generation Sequencing Market

Developments in NGS Technology

Next generation sequencing (NGS) has advanced technologically, transforming genomic research and applications in a number of industries. These developments include improvements in data processing techniques, chemistry, and sequencing platforms. Larger volumes of sequencing data can now be captured more quickly and affordably because to enhanced sequencing platforms' higher throughput. The market statistics for next-generation sequencing are being positively impacted by this. Furthermore, improvements in read length and sequencing accuracy brought about by advances in sequencing chemistry enable better detection of genomic variants and increased genome coverage. Additionally, new advances in computing methods and data analytic tools have made it easier to process, analyze, and interpret NGS data, enabling researchers to more quickly draw pertinent conclusions from massive genomic datasets.

Overall, NGS's technological developments keep the sector growing and expanding its uses. Ultima Genomics, for example, collaborated with Nvidia to use artificial intelligence (AI) in several phases of DNA sequencing and analysis. Additionally, Ultima's tool makes use of the Nvidia Clara AI computing platform and Nvidia A30 GPUs to offer customers who require high-volume genomic investigations extremely accurate secondary and primary analysis. Therefore, the industry is anticipated to see new goods and services as a result of the use of AI and cloud computing.


Growing Use of NGS in Medical Applications

Many facets of healthcare are changing as a result of the rapidly growing use of next generation sequencing (NGS) in clinical applications. By offering previously unheard-of insights into disease genetics, NGS is transforming clinical practice in a variety of ways, from diagnosis to individualized therapy plans. NGS provides quick and thorough analysis of genomic variants in diagnostic tests, making it possible to precisely diagnose infectious pathogens, rare genetic abnormalities, and cancer mutations. Prenatal screening, pharmacogenomics, and the detection of rare diseases are among its functions, providing doctors with vital genetic data for individualized patient care. To enhance precision oncology, for example, OmniSeq and LabCorp, a life science business based in the United States, unveiled OmniSeq INSIGHTsm, a next-generation sequencing test.

Furthermore, precision medicine initiatives, focused therapy selection, and the discovery of new drugs in clinical trials are all being accelerated by NGS-based genomic profiling. NGS technology is being incorporated into clinical processes as it advances and becomes more reasonably priced. For example, Agilent Technologies Inc., a U.S.-based company, developed the NGS-based Agilent Sure Select Cancer CGP Assay to advance precision oncology. Therefore, it is anticipated that the growing emphasis of industry players on NGS for precision oncology would increase demand for next-generation sequencing.


Growing Need for Data Analysis and Bioinformatics Tools

To get the most out of next generation sequencing (NGS) data, bioinformatics tools and data analysis solutions are essential. Processing, evaluating, and understanding the massive amounts of genomic data produced by NGS technology require these computational resources. For tasks including read alignment, variant calling, de novo assembly, differential gene expression analysis, and pathway enrichment, bioinformatics tools comprise a broad range of approaches and software programs. Additionally, data analysis tools offer integrated processes and user-friendly interfaces that simplify the processing of NGS data for researchers and physicians who need sophisticated computer skills.

To maximize the insights from NGS investigations and improve our knowledge of genomics, transcriptomics, and epigenomics, bioinformatics tools and data processing solutions must be continuously developed and updated. For example, My Intelligent Machines (MIMs) introduced their software for oncology drug development. In a different case, ARUP introduced Rio, a bioinformatics analytics platform that facilitates the production of quicker findings for tests involving next-generation sequencing.


Challenges in the Next Generation Sequencing Market

High Costs of NGS Infrastructure

One major obstacle is still the high cost of Next Generation Sequencing (NGS) infrastructure, particularly for emerging countries, clinical settings, and smaller research facilities. The initial outlay for NGS equipment, chemicals, and associated infrastructure can be unaffordable, even though sequencing costs per base have dropped. The financial burden is further increased by operating expenses, such as the continuous purchase of consumables and reagents and the requirement for qualified staff. The broad use of NGS technology may be constrained by these ongoing costs, which might put a pressure on organizations with tight resources. This financial obstacle may make it more difficult for smaller labs and areas with limited resources to translate NGS advancements into useful, everyday applications for clinical and research settings.


Clinical Validation and Regulatory Approval

There is a lack of large-scale clinical validation for Next Generation Sequencing (NGS), especially for newer applications like liquid biopsy and gene therapy, and regulatory bodies like the FDA are cautious about approving NGS-based tests, especially for personalized medicine, due to concerns about accuracy, reliability, and long-term clinical outcomes. The regulatory environment for genomic testing also varies greatly across regions, with the FDA, CLIA, and CAP imposing different standards in the U.S. and Europe following CE marking guidelines. These complicated and region-specific regulations can delay the approval and widespread use of NGS technologies, which makes it more difficult for innovations to quickly reach clinical practice.


Reagents and consumables represent a major segment of the NGS market

The reagents and consumables phase held one of the most significant shares in the global next-generation sequencing market. This, in particular, is attributed to the recurrent utilization and high demand for reagents and consumables in NGS's commercial and research applications. These consumables encompass sample preparation kits as well as kits for target enrichment. The adoption of NGS reagents and consumables has expanded as most pharmaceutical agencies and research institutes are utilizing NGS for several diagnostic programs and cancer studies.


Diagnostic applications are a key segment driving the NGS market growth

Diagnostic applications are pivotal in the global Next-Generation Sequencing (NGS) market. This is due to their direct effect on healthcare. NGS's capability to research genetic versions enables precise disease prognosis, diagnosis, and personalized remedy selection. This section addresses important wishes in oncology, uncommon diseases, infectious illnesses, and prenatal screening, driving market increase. As healthcare structures prioritize precision medicine and genomic-pushed tactics, diagnostic applications become a cornerstone, contributing notably to the prominence and expansion of the global NGS market.


Sequencing by synthesis is a leading technology in NGS market

Sequencing by synthesis (SBS) is one of the most famous technologies in the global Next-Generation Sequencing (NGS) market. This technology permits immediate and correct sequencing by constructing complementary DNA strands step by step. Its significant use is pushed through its capability to utilize vast quantities of data, produce low mistake rates, and be cost-effective, making it ideal for various programs in studies, diagnostics, and customized medicine. As the desire for big-scale genomic evaluation continues to develop, SBS will remain an important technology, expanding the worldwide NGS market in the coming years.


Academic and clinical research centers are key drivers of market growth

The academic and clinical research facilities segment is anticipated to be one of the quickest-growing segments within the market. This is due to the increasing use of next-generation sequencing (NGS) in cancer research. This technology enables the identification of new cancer-related genes, the examination of tumor heterogeneity, and the detection of alterations contributing to tumorigenesis. Also, providing scientific studies through market entities is predicted to offer ample opportunities for enhancing and detecting goals in this area.


Next Generation Sequencing Market Overview by Regions

By countries, the global Next Generation Sequencing market is divided into United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherland, Turkey, China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand, Brazil, Mexico, Argentina, Saudi Arabia, UAE, South Africa, and Rest of the World.


United States Next Generation Sequencing Market

Because of its strong healthcare system, large R&D expenditures, and innovative breakthroughs, the US is a prominent market for Next Generation Sequencing (NGS). In clinical diagnostics, NGS technologies are extensively utilized, especially in the testing of infectious diseases, genetic disorders, and oncology. Strong financing support, research partnerships, and a well-established regulatory framework (FDA, CLIA) all help the industry. But problems like exorbitant prices, problems with reimbursement, and complicated regulations still exist. The market is expanding due to the rising demand for customized treatment and the incorporation of NGS into standard clinical procedures. In the upcoming years, the market's growth is anticipated to be further accelerated by academic and research institutions, as well as by the growing use of gene therapy and liquid biopsy.

For example, according to 2022 data from the Canada Cancer Society, around 6,700 Canadians received a leukemia diagnosis in 2021, with 2,700 being women and 4,000 being men. Additionally, according to estimates from the American Cancer Society for 2023, there will likely be about 59,610 new leukemia cases and 20,380 new cases of acute myeloid leukemia (AML) diagnosed in the US. As a result, the increased prevalence of these illnesses is boosting the market in the area by increasing the use of devices based on NGS technology.

Additionally, more funds will be allocated to genomes research, which is anticipated to boost the market's expansion and the adoption of NGS-based products. In May 2022, for instance, the National Institutes of Health (NIH) announced that the United States would spend USD 1,220 million on cancer genomics, up from USD 1,160 million in 2021.


Germany Next Generation Sequencing Market

Driven by robust healthcare infrastructure, academic research, and biotechnology breakthroughs, Germany is a major player in the European Next Generation Sequencing (NGS) market. In clinical diagnostics, NGS technologies are being used more and more, especially in prenatal testing, rare genetic illnesses, and oncology. Clinical NGS integration is made easier by Germany's well-established regulatory framework, which includes CE marking for medical products. Universities and research centers are essential to the advancement of NGS applications. The need for genomic research and tailored therapy is driving business expansion despite exorbitant prices and difficulties with payment. Furthermore, it is anticipated that Germany will become a major market in Europe due to its leadership in genomic data efforts like the National Genome Project, which will spur innovation and adoption of NGS technology.


India Next Generation Sequencing Market

The market for next-generation sequencing (NGS) in India is expanding significantly due to advances in genomic research, growing healthcare spending, and a growing need for tailored medicine. Academic and research institutes are helping to promote the use of NGS in clinical diagnostics, which includes oncology, genetic disorders, and infectious diseases. Notwithstanding obstacles such as exorbitant upfront expenses, restricted reimbursement guidelines, and a shortage of qualified experts, India's sizable population and varied genetic terrain provide special prospects for NGS applications, especially in epidemiology and public health research. The industry is anticipated to develop even faster as a result of government programs to support genomics and biotechnology research as well as rising awareness of genetic testing. India is becoming a major force in the worldwide NGS market, especially in the field of genomics research.

Additionally, the region's growing Covid-19 case count will increase demand for Next-Generation Sequencing. For example, according to the WHO data, up until December 23, 2021, there were approximately 34,765,976 confirmed COVID-19 infections and 7,495 new cases recorded in India. Additionally, government campaigns to increase public knowledge of molecular diagnosis and better healthcare infrastructure will support the growth of the Next-Generation Sequencing market in these areas.


United Arab Emirates Next Generation Sequencing Market

The United Arab Emirates' (UAE) Next Generation Sequencing (NGS) market is growing quickly due to developments in biotechnology, healthcare, and research facilities. With growing investments in genomic research, especially in personalized medicine, oncology, and rare genetic illnesses, the UAE has emerged as a regional center for medical innovation. With the help of government plans to establish the UAE as a leader in precision medicine and healthcare, NGS is becoming more popular in both clinical diagnostics and academic research. The expanding healthcare industry and smart partnerships with international NGS firms are driving market expansion despite obstacles including high costs and the demand for qualified workers. The UAE is positioned to emerge as a major force in the Middle Eastern NGS market as healthcare standards grow and genomic technology use increases.


Product – Market breakup in 3 viewpoints:
1. Instruments
2. Reagents & Consumables
3. Services


Application – Market breakup in 5 viewpoints:
1. Diagnostics
2. Agriculture and Animal Research
3. Drug Discovery
4. Personalized Medicine and Genetic Screening
5. Others


Technology – Market breakup in 5 viewpoints:
1. Sequencing by Synthesis
2. Ion Semiconductor Sequencing
3. Single-Molecule Read Time Sequencing
4. Nanopore Sequencing
5. Others


End-Users – Market breakup in 4 viewpoints:
1. Academic and Clinical Research Centers
2. Pharmaceutical and Biotechnology Companies
3. Hospitals and Clinics
4. Others


Countries – Market of 25 Countries:
1 North America

1.1 United States
1.2 Canada

2 Europe

2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherlands
2.8 Turkey

3 Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand

4 Latin America

4.1 Brazil
4.2 Mexico
4.3 Argentina

5 Middle East & Africa

5.1 Saudi Arabia
5.2 United Arab Emirates
5.3 South Africa


All the Key players have been covered from 3 Viewpoints:
• Overview
• Recent Development
• Revenue Analysis


Company Analysis:
1. Illumina
2. Thermo Fisher Scientific
3. Pacific Biosciences
4. QIAGEN N.V.
5. Roche
6. Bio-Rad Laboratories, Inc.
7. Takara Bio Inc.
8. Hamilton Company
9. Geneious
10. BioMérieux SA


Key Questions Answered in Report:
1. How big is the Next Generation Sequencing industry?
The global Next Generation Sequencing market size was valued at US$ 12.52 billion in 2024 and is expected to reach US$ 56.25 billion in 2033.

2. What is the Next Generation Sequencing growth rate?
The global Next Generation Sequencing market is expected to expand at a compound annual growth rate (CAGR) of 18.17% from 2025 to 2033.

3. Who are the key players in Next Generation Sequencing industry?
Some key players operating in the Next Generation Sequencing market includes Beyond Meat, Conagra Brands, Maple Leaf Foods Inc, Tyson Foods Inc, Kellanavo, Archer Daniels Midland, US Foods Holding, and Hormel Foods Corporation.

4. What are the factors driving the Next Generation Sequencing industry?
Advances in genomics, rising demand for personalized medicine, declining sequencing costs, expanding applications in rare diseases and oncology, government support, and technological advancements in sequencing platforms and bioinformatics are some of the factors propelling the next generation sequencing market.

5. Which Region held the largest market share in the Next Generation Sequencing industry?
North America is expected to hold the largest market share in the industry.

6. What segments are covered in the Next Generation Sequencing Market report?
Product, Application, Technology, End-User and Countries segment are covered in this report.

ページTOPに戻る

Table of Contents

1. Introduction


2. Research & Methodology


3. Executive Summary


4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges


5. Global Next Generation Sequencing Market


6. Market Share
6.1 By Product
6.2 By Application
6.3 By Technology
6.4 By End User
6.5 By Countries


7. Product
7.1 Instruments
7.2 Reagents & Consumables
7.3 Services


8. Application
8.1 Diagnostics
8.2 Agriculture and Animal Research
8.3 Drug Discovery
8.4 Personalized Medicine and Genetic Screening
8.5 Others


9. Technology
9.1 Sequencing by Synthesis
9.2 Ion Semiconductor Sequencing
9.3 Single Molecule Read Time Sequencing
9.4 Nanopore Sequencing
9.5 Others


10. End User
10.1 Academic and Clinical Research Centers
10.2 Pharmaceutical and Biotechnology Companies
10.3 Hospitals and Clinics
10.4 Others


11. Countries
11.1 North America

11.1.1 United States
11.1.2 Canada

11.2 Europe

11.2.1 France
11.2.2 Germany
11.2.3 Italy
11.2.4 Spain
11.2.5 United Kingdom
11.2.6 Belgium
11.2.7 Netherlands
11.2.8 Turkey

11.3 Asia Pacific

11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Thailand
11.3.6 Malaysia
11.3.7 Indonesia
11.3.8 Australia
11.3.9 New Zealand

11.4 Latin America

11.4.1 Brazil
11.4.2 Mexico
11.4.3 Argentina

11.5 Middle East & Africa

11.5.1 Saudi Arabia
11.5.2 United Arab Emirates
11.5.3 South Africa


12. Porter's Five Forces Analysis
12.1 Threat of New Entry
12.2 The Bargaining Power of Buyer
12.3 Threat of Substitution
12.4 The Bargaining Power of Supplier
12.5 Competitive Rivalry


13. SWOT Analysis
13.1 Strengths
13.2 Weaknesses
13.3 Opportunities
13.4 Threats


14. Key Players Analysis
14.1 Illumina

14.1.1 Overview
14.1.2 Recent Development
14.1.3 Revenue

14.2 Thermo Fisher Scientific

14.2.1 Overview
14.2.2 Recent Development
14.2.3 Revenue

14.3 Pacific Biosciences

14.3.1 Overview
14.3.2 Recent Development
14.3.3 Revenue

14.4 QIAGEN N.V

14.4.1 Overview
14.4.2 Recent Development
14.4.3 Revenue

14.5 Roche

14.5.1 Overview
14.5.2 Recent Development
14.5.3 Revenue

14.6 Bio-Rad Laboratories, Inc.

14.6.1 Overview
14.6.2 Recent Development
14.6.3 Revenue

14.7 Takara Bio Inc

14.7.1 Overview
14.7.2 Recent Development
14.7.3 Revenue

14.8 Hamilton Company

14.8.1 Overview
14.8.2 Recent Development
14.8.3 Revenue

14.9 Geneious

14.9.1 Overview
14.9.2 Recent Development
14.9.3 Revenue

14.10 BioMérieux SA

14.10.1 Overview
14.10.2 Recent Development
14.10.3 Revenue